Literature DB >> 25199777

In vitro potential of Lycosin-I as an alternative antimicrobial drug for treatment of multidrug-resistant Acinetobacter baumannii infections.

Ling Wang1, Yong-Jun Wang1, Yin-Yin Liu1, Hui Li1, Ling-Xia Guo1, Zhong-Hua Liu2, Xiao-Liu Shi3, Min Hu3.   

Abstract

The resistance of multidrug-resistant Acinetobacter baumannii (MDRAB) isolates to most traditional antibiotics results in huge challenges for infection therapy. We investigated the in vitro activities of both l- and d-lycosin-I against MDRAB. These two compounds displayed high antibacterial activities and rapid bactericidal effects against MDRAB. Moreover, the compounds retained their activity even at high salt (Mg(2+) or Ca(2+)) concentrations. These results demonstrate the potential of lycosin-I to be developed as a new antibiotic.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25199777      PMCID: PMC4249444          DOI: 10.1128/AAC.03279-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  28 in total

Review 1.  Why and how are peptide-lipid interactions utilized for self-defense? Magainins and tachyplesins as archetypes.

Authors:  K Matsuzaki
Journal:  Biochim Biophys Acta       Date:  1999-12-15

2.  Longitudinal epidemiology of multidrug-resistant (MDR) Acinetobacter species in a tertiary care hospital.

Authors:  Ji Hoon Baang; Peter Axelrod; Brooke K Decker; Andrea M Hujer; Georgia Dash; Allan R Truant; Robert A Bonomo; Thomas Fekete
Journal:  Am J Infect Control       Date:  2011-08-11       Impact factor: 2.918

3.  Spread of multidrug carbapenem-resistant Acinetobacter baumannii in different wards of an Italian hospital.

Authors:  Maria Luisa Cristina; Anna Maria Spagnolo; Gianluca Ottria; Marina Sartini; Paolo Orlando; Fernanda Perdelli
Journal:  Am J Infect Control       Date:  2011-06-25       Impact factor: 2.918

4.  Risk factors and outcome analysis of acinetobacter baumannii complex bacteremia in critical patients.

Authors:  Hao-Yuan Lee; Chyi-Liang Chen; Si-Ru Wu; Chih-Wei Huang; Cheng-Hsun Chiu
Journal:  Crit Care Med       Date:  2014-05       Impact factor: 7.598

5.  Antibacterial properties of dermaseptin S4 derivatives with in vivo activity.

Authors:  Shiri Navon-Venezia; Rina Feder; Leonid Gaidukov; Yehuda Carmeli; Amram Mor
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

6.  Functional characterization of naturally occurring melittin peptide isoforms in two honey bee species, Apis mellifera and Apis cerana.

Authors:  Doori Park; Je Won Jung; Mi Ok Lee; Si Young Lee; Boyun Kim; Hye Jun Jin; Jiyoung Kim; Young-Joon Ahn; Ki Won Lee; Yong Sang Song; Seunghun Hong; James E Womack; Hyung Wook Kwon
Journal:  Peptides       Date:  2014-02-08       Impact factor: 3.750

7.  Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens.

Authors:  Garyphallia Poulakou; Flora V Kontopidou; Elisabeth Paramythiotou; Maria Kompoti; Maria Katsiari; Efstratios Mainas; Chara Nicolaou; Dimitrios Yphantis; Anastasia Antoniadou; Eleftheria Trikka-Graphakos; Zoi Roussou; Phyllis Clouva; Nina Maguina; Kyriaki Kanellakopoulou; Apostolos Armaganidis; Helen Giamarellou
Journal:  J Infect       Date:  2009-04       Impact factor: 6.072

8.  In vitro pharmacodynamics of polymyxin B and tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii.

Authors:  Mao Hagihara; Seth T Housman; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2013-11-25       Impact factor: 5.191

9.  New insights into dissemination and variation of the health care-associated pathogen Acinetobacter baumannii from genomic analysis.

Authors:  Meredith S Wright; Daniel H Haft; Derek M Harkins; Federico Perez; Kristine M Hujer; Saralee Bajaksouzian; Michael F Benard; Michael R Jacobs; Robert A Bonomo; Mark D Adams
Journal:  MBio       Date:  2014-01-21       Impact factor: 7.867

10.  Antimicrobial peptides: versatile biological properties.

Authors:  Muthuirulan Pushpanathan; Paramasamy Gunasekaran; Jeyaprakash Rajendhran
Journal:  Int J Pept       Date:  2013-06-26
View more
  7 in total

Review 1.  Anticancer, antimicrobial, and analgesic activities of spider venoms.

Authors:  Hassan M Akef
Journal:  Toxicol Res (Camb)       Date:  2018-03-08       Impact factor: 3.524

2.  The peptide lycosin-I attenuates TNF-α-induced inflammation in human umbilical vein endothelial cells via IκB/NF-κB signaling pathway.

Authors:  Xianyao Li; Yaqin Tang; Binbin Ma; Zheng Wang; Jinying Jiang; Shengjie Hou; Shuhang Wang; Jie Zhang; Meichun Deng; Zhigui Duan; Xing Tang; Alex F Chen; Liping Jiang
Journal:  Inflamm Res       Date:  2018-03-10       Impact factor: 4.575

3.  Dual-sensitive antibacterial peptide nanoparticles prevent dental caries.

Authors:  Peng Zhang; Saizhi Wu; Jinting Li; Xiaoshuang Bu; Xiaoping Dong; Ninglin Chen; Fengjiao Li; Jingyu Zhu; Longkang Sang; Youlin Zeng; Songping Liang; Zhilin Yu; Zhonghua Liu
Journal:  Theranostics       Date:  2022-06-13       Impact factor: 11.600

4.  Clinical experience with tigecycline in the treatment of hospital-acquired pneumonia caused by multidrug resistant Acinetobacter baumannii.

Authors:  Yangang Zhou; Xumin Chen; Ping Xu; Yan Zhu; Kuangguo Wang; Daxiong Xiang; Feng Wang; Hoan Linh Banh
Journal:  BMC Pharmacol Toxicol       Date:  2019-04-25       Impact factor: 2.483

Review 5.  Cell-Penetrating Peptides Derived from Animal Venoms and Toxins.

Authors:  Gandhi Rádis-Baptista
Journal:  Toxins (Basel)       Date:  2021-02-15       Impact factor: 4.546

Review 6.  Antimicrobial Peptides with Anti-Candida Activity.

Authors:  Aitzol Perez-Rodriguez; Elena Eraso; Guillermo Quindós; Estibaliz Mateo
Journal:  Int J Mol Sci       Date:  2022-08-17       Impact factor: 6.208

7.  The Spider Venom Peptide Lycosin-II Has Potent Antimicrobial Activity against Clinically Isolated Bacteria.

Authors:  Yongjun Wang; Ling Wang; Huali Yang; Haoliang Xiao; Athar Farooq; Zhonghua Liu; Min Hu; Xiaoliu Shi
Journal:  Toxins (Basel)       Date:  2016-04-26       Impact factor: 4.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.